Trial · NCT00778817
Adverse events25
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 25
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Dehydration | Metabolism and nutrition disorders | Chemotherapy and Monoclonal Antibody Therapy | 1 | 20 | |
| other | Fatigue | General disorders | Chemotherapy and Monoclonal Antibody Therapy | 1 | 20 | |
| other | Hyperglycemia | Metabolism and nutrition disorders | Chemotherapy and Monoclonal Antibody Therapy | 2 | 20 | |
| serious | Abdominal pain | Gastrointestinal disorders | Chemotherapy and Monoclonal Antibody Therapy | 1 | 20 | |
| serious | Alanine aminotransferase increased | Investigations | Chemotherapy and Monoclonal Antibody Therapy | 1 | 20 | |
| serious | Anorexia | Metabolism and nutrition disorders | Chemotherapy and Monoclonal Antibody Therapy | 1 | 20 | |
| serious | Cholesterol high | Investigations | Chemotherapy and Monoclonal Antibody Therapy | 1 | 20 | |
| serious | Cognitive disturbance | Nervous system disorders | Chemotherapy and Monoclonal Antibody Therapy | 1 | 20 | |
| serious | Confusion | Psychiatric disorders | Chemotherapy and Monoclonal Antibody Therapy | 1 | 20 | |
| serious | Creatinine increased | Investigations | Chemotherapy and Monoclonal Antibody Therapy | 1 | 20 | |
| serious | Dehydration | Metabolism and nutrition disorders | Chemotherapy and Monoclonal Antibody Therapy | 2 | 20 | |
| serious | Depressed level of consciousness | Nervous system disorders | Chemotherapy and Monoclonal Antibody Therapy | 1 | 20 | |
| serious | Diarrhea | Gastrointestinal disorders | Chemotherapy and Monoclonal Antibody Therapy | 1 | 20 | |
| serious | Dizziness | Nervous system disorders | Chemotherapy and Monoclonal Antibody Therapy | 1 | 20 | |
| serious | Fatigue | General disorders | Chemotherapy and Monoclonal Antibody Therapy | 1 | 20 | |
| serious | Fever | General disorders | Chemotherapy and Monoclonal Antibody Therapy | 1 | 20 | |
| serious | Generalized muscle weakness | Musculoskeletal and connective tissue disorders | Chemotherapy and Monoclonal Antibody Therapy | 1 | 20 | |
| serious | Hyperglycemia | Metabolism and nutrition disorders | Chemotherapy and Monoclonal Antibody Therapy | 1 | 20 | |
| serious | Hypertriglyceridemia | Metabolism and nutrition disorders | Chemotherapy and Monoclonal Antibody Therapy | 1 | 20 | |
| serious | Hypoglycemia | Metabolism and nutrition disorders | Chemotherapy and Monoclonal Antibody Therapy | 1 | 20 |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00778817/events